| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Keros Therapeutics, Inc. | CHIEF FINANCIAL OFFICER | Common Stock | 44K | $1.94M | $44.01 | Feb 18, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | Feb 18, 2025 | 1 | $0 | 4 | Feb 19, 2025 | CHIEF FINANCIAL OFFICER |
| KROS | Keros Therapeutics, Inc. | Feb 13, 2024 | 1 | $0 | 4 | Feb 15, 2024 | CHIEF FINANCIAL OFFICER |
| KROS | Keros Therapeutics, Inc. | Jan 4, 2024 | 2 | -$1.17M | 4/A | Jan 24, 2025 | CHIEF FINANCIAL OFFICER |
| KROS | Keros Therapeutics, Inc. | Nov 4, 2023 | 3 | -$1.17M | 4 | Jan 8, 2024 | Chief Financial Officer |
| KROS | Keros Therapeutics, Inc. | Jun 8, 2023 | 9 | -$1.22M | 4 | Jun 12, 2023 | Chief Financial Officer |
| KROS | Keros Therapeutics, Inc. | Feb 16, 2023 | 1 | $0 | 4 | Feb 17, 2023 | Chief Financial Officer |
| KROS | Keros Therapeutics, Inc. | Jan 21, 2022 | 1 | $0 | 4 | Jan 25, 2022 | Chief Financial Officer |